Uric Acid: Where Are We?

Journal of Clinical Hypertension

Volumn 15, Issue 1, 2013, Pages 5-6

  Rosendorff, Clive ^a,b   Jogendra, Mather R D ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALLOPURINOL; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; APOLIPOPROTEIN A; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATININE; D DIMER; FIBRINOGEN; HOMOCYSTEINE; LIPOPROTEIN A; NITRIC OXIDE; PHOSPHOLIPASE A2; PLASMINOGEN ACTIVATOR INHIBITOR 1; RENIN; URIC ACID; XANTHINE OXIDASE;

ABDOMINAL OBESITY; ACUTE HEART INFARCTION; ALCOHOL CONSUMPTION; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CIRCADIAN RHYTHM; DIABETES MELLITUS; DIETARY INTAKE; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; FRUIT; GLOMERULOSCLEROSIS; GOUT; HUMAN; HYPERTENSION; HYPERURICEMIA; ISCHEMIC HEART DISEASE; KIDNEY FIBROSIS; KIDNEY HYPERTROPHY; KIDNEY ISCHEMIA; MORBIDITY; NEPHROLITHIASIS; NOTE; PRIORITY JOURNAL; SMOKING; SOCIAL PSYCHOLOGY; URIC ACID BLOOD LEVEL; VEGETABLE;

ANIMALS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAUSALITY; CIRCADIAN RHYTHM; HUMANS; HYPERTENSION; RATS; URIC ACID;

EID: 84871931238     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12034     Document Type: Note

References (24)

1. Scheele VQ. Examen chemicum calculi urinari. Opuscula. 1776;2:73.
2. Garrod A. Observations on certain pathological conditions of the blood and urine in gout, rheumatism and Bright's disease. Med Chir Trans. 1848;31:83-97.
3. Yusuf S, Hawken S, Ounpuu S, et al.Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
4. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I Epidemiologic Follow-up Study, 1971-1992. JAMA. 2000;283:2404-2410.
5. Freedman DS, Williamson DF, Gunter EW, Byers T. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1995;141:637-644.
6. Brand FN, McGee DL, Kannel WB, et al.Hyperuricemia as a risk factor of coronary heart disease: The Framingham Study. Am J Epidemiol. 1985;121:11-18.
7. Niskanen LK, Laaksonen DE, Nyyssönen K, et al.Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164:1546-1551.
8. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation. 2007;116:894-900.
9. Anker SD, Doehner W, Rauchhaus M, et al.Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003;107:1991-1997.
10. Turak O, Özcan F, Tok D, et al.Serum uric acid, inflammation and nondipping circadian pattern in essential hypertension. J Clin Hypertens. 2012;???:00.
11. Masuo K, Kawaguchi H, Mikami H, et al.Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation. Hypertension. 2003;42:474-480.
12. Nakanishi K, Okamoto M, Yoshida H, et al.Serum uric acid and risk for development of hypertension and impaired fasting glucose or type II diabetes in Japanese male office workers. Eur J Epidemiol. 2003;18:523-530.
13. Rho YH, Zhu Y, Choi HK. The epidemiology of uric acid and fructose. Semin Nephrol. 2011;31:401-419.
14. Mazzali M, Hughes J, Kim YG, et al.Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001;38:1101-1106.
15. Kang D-H, Nakagawa T, Feng L, et al.A role for uric acid in the progression of renal disease. J Am Soc Nephrol. 2002;13:2888-2897.
16. Sanchez-Lozada LG, Tapia E, Avila-Cosada C, et al.Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol. 2002;283:F1105-F1110.
17. Doehner W, Landmeisser U. Xanthine oxidase and uric acid in cardiovasacular disease:clinical impact and therapeutic options. Semin Nephrol. 2011;31:433-440.
18. Doehner W, Schoene N, Rauchhaus M, et al.Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105:2619-2624.
19. Butler R, Morris AD, Belch JJF, et al.Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000;35:746-751.
20. Farquarson CAJ, Butler R, Hill A, et al.Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221-226.
21. Doehner W, Anker SD. Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?Heart. 2005;91:707-709.
22. Guthikonda S, Sinkey C, Barenz T, Haynes WG. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation. 2003;107:416-421.
23. Noman A, Ang DS, Ogston S, et al.Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomized, placebo controlled crossover trial. Lancet. 2010;375:2161-2167.
24. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51-59.